重组人干扰素α-2b注射液治疗病毒性肝炎的临床分析

Clinical analysis of α-interferon treatment to viral hepatitis

目的 探讨重组人干扰素α-2b注射液治疗病毒性肝炎的效果.方法 回顾性分析本院2011年1月～2012年10月收治的60例病毒性肝炎患者的临床资料,将所有患者随机分为治疗组和对照组,观察两组患者的治疗效果.结果 治疗组患者在用药1个月后ALT的复常率为60.00％,3个月后的ALT复常率为76.67％,6个月后的ALT复常率是93.33％,停止用药后6个月的复常率为86.67％；对照组患者在用药1个月后的ALT复常率为30.00％,3个月后的ALT复常率为50.00％,6个月后的ALT复常率为70.00％,停止用药后6个月的复常率为63.33％,两组间比较,差异均有统计学意义（P＜0.05）.结论 重组人干扰素α-2b注射液治疗病毒性肝炎效果良好,能够减轻患者痛苦,帮助患者早日恢复健康,值得在临床中广泛推广.

Objective To research and discuss about the clinical efficacy of human recombinant interferon a-2b injec- tion in treatment to viral hepatitis. Methods The clinical data of 60 cases of viral hepatitis patients treated in our hos- pital from Jan. 2011 to Oct. 2012 was analyzed retrospectively,all the patients were randomly divided into treatment group and control group.Treatment efficacies of the two groups were observed. Results The patients in treatment group had a 60.00%,76.67% and 93.33% normalization rate of ALT after one,three and six months of treatment respectively. The normalization rate of ALT was 86.67% after 6 months of drug withdraw.The patients in control group had a 30.00%,50.00% and 70.00% normalization rate of ALT after one,three and six months of treatment respectively.The normalization rate of ALT was 63.33% after 6 months of drug withdraw.With the comparison of the two groups,the dif- ference was statistically significant （P〈0.05）. Conclusion Human recombinant interferon a-2b injection has favorable effect in the treatment of viral hepatitis,it can reduce the suffering of patients,help to restore the health of the patient as soon as possible and is worthy of widely application in clinical medicine.